Aug 2026· Biomolecules & Therapeutics· Vol 34, pp. 1192 - 1206· 0 citations· 30 references
Medicine
TL;DR
Collectively, emodin suppresses CRCSC characteristics in vitro by downregulating Wnt/β-catenin signaling and inducing AIF-associated caspase-independent apoptosis, highlighting its therapeutic potential against CRC.
Abstract
Colorectal cancer (CRC) remains a major cause of cancer-related mortality due to therapeutic resistance. Because colorectal cancer stem-like cells (CRCSCs) play a central role in tumor initiation and progression, therapeutic strategies addressing CSC-enriched populations are urgently needed. In this study, we investigated the anticancer effects of emodin, a natural anthraquinone, in CSC-enriched tumorsphere models. Emodin significantly suppressed the viability and self-renewal capacity of HCT116- and SW480-derived CSCs. It induced G0/G1 cell cycle arrest and markedly downregulated stemness-associated markers (CD44, CD133, ALDH1A1, SOX2, NANOG, and OCT4). Importantly, emodin-induced cell death was characterized by mitochondrial dysfunction, increased mitochondrial reactive oxygen species, loss of membrane potential, and nuclear translocation of apoptosis-inducing factor (AIF). This cytotoxicity was not rescued by the pan-caspase inhibitor Z-VAD-FMK, confirming caspase-independent apoptosis. Furthermore, network pharmacology and experimental validation identified GSK3β as a key target. Emodin reduced Wnt/β-catenin signaling by decreasing β-catenin stabilization and nuclear accumulation. Crucially, a rescue experiment utilizing LiCl confirmed that emodin’s suppressive effects are mechanistically dependent on the GSK3β/Wnt/β-catenin axis. Collectively, emodin suppresses CRCSC characteristics in vitro by downregulating Wnt/β-catenin signaling and inducing AIF-associated caspase-independent apoptosis, highlighting its therapeutic potential against CRC.
Dysregulated wnt/β-catenin signaling cascades drive self-renewal, proliferation, differentiation, and therapeutic resistance in cancer stem cells (CSCs), thus contributing to their tumor aggression and poor clinical outcomes. Earlier, we demonstrated that a glucocorticoid receptor (GR)-targeted liposomal formulation...
Breast cancer continues to represent a major contributor to cancer-related mortality, creating a severe public health burden worldwide. Adjuvant therapy is essential for nearly fifty percent of breast cancer patients following surgery to mitigate recurrence. Consequently, the use of effective chemotherapeutic agents to...
Omniah A. Mansouri, Tahani Bakhsh· Journal of King Saud Univers...· 0 citations
Triple-negative breast cancer (TNBC) is widely
considered as one of the most challenging and
aggressive forms of breast cancer with poor prognosis
and limited treatment options. TNBC progression is
associated with aberrant dysregulation of microRNAs
(miRNAs) and oncogenic pathways like PI3K/AKT,
which promote cell prol...
Sharanya K., A. K. A. Mandal· Research journal of biotechn...· 0 citations
Colorectal cancer (CRC) is the third most prevalent cancer globally, with limited effective treatment options and significant chemotherapy resistance. Saikosaponin A (SSA), a triterpenoid saponin from Radix Bupleuri, exhibits anti-inflammatory and antitumor properties, but its mechanism of action in CRC remains und...
Xiu-Xiu Zhang, Jing-Ling Yang, Wang-Wei Zhang et al.· Food Science and Human Welln...· 0 citations
ST6GAL1-mediated α2,6-sialylation of EGFR contributes to the maintenance of CSLC-associated paclitaxel resistance through mTOR-SOX2/BMI1 signaling, which identifies ST6GAL1-dependent EGFR sialylation as a potential therapeutic target in CSLC-associated chemoresistance.
Yu-Xi Yang, Bing-Hui Liang, W. Hong et al.· Cancer Drug Resistance· 1 citation
Narciclasine is a promising natural-product-derived lead compound for further preclinical evaluation in HELLS-associated CRC vulnerabilities and is associated with HELLS downregulation, DNA damage-associated signaling, and apoptosis in CRC cells.
Yoon-Mi Lee, Su-Min Han, G. Park et al.· Pharmaceuticals· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.